Castle Biosciences Stock Fundamentals
| CSTL Stock | USD 29.81 0.93 3.22% |
Castle Biosciences fundamentals help investors to digest information that contributes to Castle Biosciences' financial success or failures. It also enables traders to predict the movement of Castle Stock. The fundamental analysis module provides a way to measure Castle Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Castle Biosciences stock.
At this time, Castle Biosciences' Gross Profit is quite stable compared to the past year. Other Operating Expenses is expected to rise to about 302.2 M this year, although the value of Selling General Administrative will most likely fall to about 50.2 M. Castle | Select Account or Indicator |
Castle Biosciences Company Operating Margin Analysis
Castle Biosciences' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Castle Biosciences Operating Margin | 0.06 % |
Most of Castle Biosciences' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Castle Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Castle Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Castle Biosciences has an Operating Margin of 0.0592%. This is 100.17% lower than that of the Biotechnology sector and 100.09% lower than that of the Health Care industry. The operating margin for all United States stocks is 101.07% lower than that of the firm.
Castle Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Castle Biosciences's current stock value. Our valuation model uses many indicators to compare Castle Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Castle Biosciences competition to find correlations between indicators driving Castle Biosciences's intrinsic value. More Info.Castle Biosciences is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . At this time, Castle Biosciences' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Castle Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Castle Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Castle Biosciences' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Castle Biosciences could also be used in its relative valuation, which is a method of valuing Castle Biosciences by comparing valuation metrics of similar companies.Castle Biosciences is currently under evaluation in operating margin category among its peers.
Castle Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Castle Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Castle Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Castle Fundamentals
| Return On Equity | 0.0147 | ||||
| Return On Asset | -0.0014 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 543.76 M | ||||
| Shares Outstanding | 28.01 M | ||||
| Shares Owned By Insiders | 3.22 % | ||||
| Shares Owned By Institutions | 95.25 % | ||||
| Number Of Shares Shorted | 1.61 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 2.59 X | ||||
| Revenue | 219.79 M | ||||
| Gross Profit | 105.03 M | ||||
| EBITDA | (45.02 M) | ||||
| Net Income | (57.47 M) | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 15.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | (5.63 M) | ||||
| Short Ratio | 4.27 X | ||||
| Earnings Per Share | 0.21 X | ||||
| Target Price | 41.56 | ||||
| Number Of Employees | 710 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 808.85 M | ||||
| Total Asset | 453.34 M | ||||
| Retained Earnings | (218.37 M) | ||||
| Working Capital | 247.97 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
| Net Asset | 453.34 M |
About Castle Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Castle Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Castle Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Castle Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 7.6 M | 8 M | |
| Total Revenue | 219.8 M | 230.8 M | |
| Cost Of Revenue | 45 M | 47.2 M | |
| Stock Based Compensation To Revenue | 0.23 | 0.24 | |
| Sales General And Administrative To Revenue | 0.30 | 0.29 | |
| Research And Ddevelopement To Revenue | 0.24 | 0.20 | |
| Capex To Revenue | 0.06 | 0.03 | |
| Revenue Per Share | 8.20 | 8.61 | |
| Ebit Per Revenue | (0.31) | (0.32) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Castle Biosciences Piotroski F Score and Castle Biosciences Altman Z Score analysis. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.